Gil Blum
Stock Analyst at Needham
(4.17)
# 661
Out of 5,182 analysts
403
Total ratings
41.75%
Success rate
18.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Reiterates: Buy | $44 | $19.33 | +127.63% | 2 | May 7, 2026 | |
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $18 | $10.89 | +65.29% | 9 | May 4, 2026 | |
| CELC Celcuity | Maintains: Buy | $122 → $157 | $131.06 | +19.79% | 25 | May 4, 2026 | |
| AUTL Autolus Therapeutics | Reiterates: Buy | $10 | $1.57 | +536.94% | 36 | Apr 9, 2026 | |
| ABSI Absci | Reiterates: Buy | $7 | $5.90 | +18.64% | 10 | Mar 30, 2026 | |
| IMCR Immunocore Holdings | Maintains: Buy | $71 → $75 | $29.58 | +153.55% | 15 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $80 → $82 | $54.83 | +49.55% | 28 | Feb 13, 2026 | |
| MREO Mereo BioPharma Group | Maintains: Buy | $5 → $3 | $0.25 | +1,101.92% | 21 | Jan 13, 2026 | |
| GERN Geron | Reiterates: Buy | $6 | $1.39 | +331.65% | 23 | Jul 26, 2024 | |
| RXRX Recursion Pharmaceuticals | Reiterates: Buy | $8 | $3.32 | +140.96% | 27 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $16.52 | +57.38% | 31 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $11 | $3.19 | +244.83% | 19 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | n/a | $19.96 | - | 39 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $7.27 | +161.35% | 4 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $6.81 | +76.21% | 33 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $8.65 | +385.55% | 17 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $6 | $1.26 | +376.19% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.39 | - | 9 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $3.63 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $6.85 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $9.76 | +391.80% | 9 | Aug 2, 2024 |
Lyell Immunopharma
May 7, 2026
Reiterates: Buy
Price Target: $44
Current: $19.33
Upside: +127.63%
Artiva Biotherapeutics
May 4, 2026
Reiterates: Buy
Price Target: $18
Current: $10.89
Upside: +65.29%
Celcuity
May 4, 2026
Maintains: Buy
Price Target: $122 → $157
Current: $131.06
Upside: +19.79%
Autolus Therapeutics
Apr 9, 2026
Reiterates: Buy
Price Target: $10
Current: $1.57
Upside: +536.94%
Absci
Mar 30, 2026
Reiterates: Buy
Price Target: $7
Current: $5.90
Upside: +18.64%
Immunocore Holdings
Feb 26, 2026
Maintains: Buy
Price Target: $71 → $75
Current: $29.58
Upside: +153.55%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Buy
Price Target: $80 → $82
Current: $54.83
Upside: +49.55%
Mereo BioPharma Group
Jan 13, 2026
Maintains: Buy
Price Target: $5 → $3
Current: $0.25
Upside: +1,101.92%
Geron
Jul 26, 2024
Reiterates: Buy
Price Target: $6
Current: $1.39
Upside: +331.65%
Recursion Pharmaceuticals
May 7, 2026
Reiterates: Buy
Price Target: $8
Current: $3.32
Upside: +140.96%
Apr 23, 2026
Reiterates: Buy
Price Target: $26
Current: $16.52
Upside: +57.38%
Mar 26, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $3.19
Upside: +244.83%
Mar 26, 2026
Reiterates: Underperform
Price Target: n/a
Current: $19.96
Upside: -
Mar 20, 2026
Reiterates: Buy
Price Target: $19
Current: $7.27
Upside: +161.35%
Mar 19, 2026
Maintains: Buy
Price Target: $10 → $12
Current: $6.81
Upside: +76.21%
Mar 9, 2026
Reiterates: Buy
Price Target: $42
Current: $8.65
Upside: +385.55%
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $1.26
Upside: +376.19%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $2.39
Upside: -
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $3.63
Upside: -
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $6.85
Upside: -
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $9.76
Upside: +391.80%